Claims for Patent: 6,290,929

Summary for Patent: 6,290,929

Title:	Cancer treatment
Abstract:	This invention is a method of treating cancer, including carcinomas and sarcomas, through the administration of a pharmaceutical composition containing an arylaldehyde 5-oxo-1,2,4-triazine hydrazide derivative. The arylaldehyde 5-oxo-1,2,4-triazine hydrazide derivative is selected from the group consisting of those with the formula: ##STR1## wherein R and R.sub.1 are independently selected from the group consisting of hydrogen and alkyl wherein the alkyl group has up to 7 carbon atoms; or a pharmaceutical salt thereof; a prodrug thereof; a metabolite thereof; and mixtures thereof. Pharmaceutical compositions comprising these compounds and their use in various treatment methods are claimed. The compounds can be used in conjunction with other chemotherapeutic agents and potentiators.
Inventor(s):	Camden; James Berger (West Chester, OH)
Assignee:	The Procter & Gamble Company (Cincinnati, OH)
Application Number:	09/627,610
Patent Claims:	1. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising a compound having the formula: ##STR12## wherein R and R.sub.1 are independently selected from the group consisting of hydrogen and alkyl wherein the alkyl group has up to 7 carbon atoms; or a pharmaceutical salt thereof; a prodrug thereof; a metabolite thereof; or mixtures thereof. 2. A method according to claim 1 wherein said cancer is prostate cancer. 3. A method according to claim 1 wherein said cancer is breast cancer. 4. A method according to claim 1 wherein said cancer is leukemia. 5. A method according to claim 1 wherein said cancer is pancreatic cancer. 6. A method according to claim 1 wherein said cancer is lung cancer. 7. A method according to claim 1 wherein said cancer is colon cancer. 8. A method according to claim 1 wherein said cancer is a sarcoma. 9. A method according to claim 1 wherein said cancer is a lymphoma. 10. A method according to claim 1 wherein R and R.sub.1 each are hydrogen, or R is methyl and R.sub.1 is hydrogen. 11. A pharmaceutical composition comprising a therapeutically effective amount of a composition comprising a compound having the formula: ##STR13## wherein R and R.sub.1 are independently selected from the group consisting of hydrogen and alkyl wherein the alkyl group has up to 7 carbon atoms; or a pharmaceutical salt thereof; a prodrug thereof; a metabolite thereof; or mixtures thereof. 12. A pharmaceutical composition of claim 11 further comprising a pharmaceutical carrier. 13. A pharmaceutical composition according to claim 12 further comprising a safe and effective amount of a potentiator. 14. A pharmaceutical composition according to claim 13, wherein said potentiator is selected from the group consisting of procodazole, triprolidine, propionic acid, monensin, an anti-sense inhibitor of the RAD51 gene, bromodeoxyuridine, dipyridamole, indomethacin, a monoclonal antibody, an anti-transferrin receptor immunotoxin, metoclopramide, 7-thia-8-oxoguanosine, N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine, N-[4[(4-fluorphenyl)sulfonyl] phenyl] acetamide, leucovorin, heparin, heparin sulfate, cimetidine, a radiosensitizer, a chemosensitizer, a hypoxic cell cytotoxic agent, muramyl dipeptide, vitamin A, 2'-deoxycoformycin, a bis-diketopiperazine derivative having potentiator activity, and dimethyl sulfoxide. 15. A pharmaceutical composition according to claim 11 further comprising a safe and effective amount of a chemotherapeutic agent. 16. A pharmaceutical composition according to claim 15 wherein said chemotherapeutic agent is selected from the group consisting of a DNA-interactive agent, alkylating agent, antimetabolite, tubulin-interactive agent, and a hormonal agent. 17. A pharmaceutical composition according to claim 15 wherein said chemotherapeutic agent is selected from the group consisting of Asparaginase, hydroxyurea, Cisplatin, Cyclophosphamide, Altretamine, Bleomycin, Dactinomycin, Doxorubicin, Etoposide, Teniposide, paclitaxel, cytoxan, 2-methoxycarbonylaminobenzimidazole and Plicamycin. 18. A pharmaceutical composition according to claim 15 wherein said chemotherapeutic agent is selected from the group consisting of Methotrexate, Fluorouracil, Fluorodeoxyuridin, CB3717, Azacitidine, Floxuridine, Mercapyopurine, 6-Thioguanine, Pentostatin, Cytarabine, and Fludarabine. 19. A pharmaceutical composition according to claim 15 further comprising a safe and effective amount of a potentiator. 20. A pharmaceutical composition according to claim 19, wherein said potentiator is selected from the group consisting of procodazole, triprolidine, propionic acid, monensin, an anti-sense inhibitor of the RAD51 gene, bromodeoxyuridine, dipyridamole, indomethacin, a monoclonal antibody, an anti-transferrin receptor immunotoxin, metoclopramide, 7-thia-8-oxoguanosine, N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine, N-[4-[(4-fluorphenyl)sulfonyl] phenyl] acetamide, leucovorin, heparin, heparin sulfate, cimetidine, a radiosensitizer, a chemosensitizer, a hypoxic cell cytotoxic agent, muramyl dipeptide, vitamin A, 2'-deoxycoformycin, a bis-diketopiperazine derivative having potentiator activity, and dimethyl sulfoxide. 21. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a compound having the formula: ##STR14## wherein R and R.sub.1 are independently selected from the group consisting of hydrogen and alkyl wherein the alkyl group has up to 7 carbon atoms; or a pharmaceutical salt thereof; a prodrug thereof; a metabolite thereof; or mixtures thereof; in a combination therapy with a safe and effective amount of a potentiator or a chemotherapeutic agent. 22. A method according to claim 21 wherein said cancer is a lymphoma. 23. A method according to claim 21 wherein said cancer is a sarcoma. 24. A method according to claim 21 wherein R and R.sub.1 each are hydrogen, or R is methyl and R.sub.1 is hydrogen. 25. A method according to claim 21 wherein said combination therapy is with a chemotherapeutic agent and the chemotherapeutic agent is selected from the group consisting of a DNA-interactive agent, an alkylating agent, an antimetabolite, a tubulin-interacive agent, and a hormonal agent. 26. A method according to claim 21 wherein said combination therapy is with a chemotherapeutic agent and the chemotherapeutic agent is selected from the group consisting of Asparaginase, hydroxyurea, Cisplatin, Cyclophosphamide, Altretamine, Bleomycin, Dactinomycin, Doxorubicin, Etoposide, Teniposide, paclitaxel, cytoxan, 2-methoxycarbonylaminobenzimidazole and Plicamycin. 27. A method according to claim 21 wherein said combination therapy is with a chemotherapeutic agent and the chemotherapeutic agent is selected from the group consisting of Methotrexate, Fluorouracil, Fluorodeoxyuridine, CB3717, Azacitidine, Floxuridine, Mercaptopurine, 6-Thioguanine, Pentostatin, Cytarabine, and Fludarabine. 28. A method according to claim 21 wherein said combination therapy is with a safe and effective amount of a potentiator. 29. A method according to claim 21, wherein said potentiator is selected from the group consisting of procodazole, triprolidine, propionic acid, monensin, an anti-sense inhibitor of the RAD51 gene, bromodeoxyuridine, dipyridamole, indomethacin, a monoclonal antibody, an anti-transferrin receptor immunotoxin, metoclopramide, 7-thia-8-oxoguanosine, N-solanesyl-N,N'-bis(3,4-dmethoxybenzyl)ethylenediamine, N-[4-[(4[fluorphenyl)sulfonyl]phenyl] acetamide, leucovorin, heparin, heparin sulfate, cimetidine, a radiosensitizer, a chemosensitizer, a hypoxic cell cytotoxic agent, muramyl dipeptide, vitamin A, 2'-deoxycoformycin, a bis-diketopiperazine derivative having potentiator activity, and dimethyl sulfoxide. 30. A liposome composition comprising a compound having the formula: ##STR15## wherein R and R.sub.1 are independently selected from the group consisting of hydrogen and alkyl wherein the alkyl group has up to 7 carbon atoms; or a pharmaceutical salt thereof; a prodrug thereof; a metabolite thereof; or mixtures thereof. 31. A liposome composition according to claim 30 wherein the liposome is selected from the group consisting of unilamellar vesicles and multilamellar vesicles. 32. A liposome composition according to claim 30 formed from a phospholipid, cholesterol, or stearylamine. 33. A pharmaceutical composition comprising the hydrochloride salt of a compound having the formula: ##STR16## wherein R and R.sub.1 are hydrogen, or R is methyl and R.sub.1 is hydrogen. 34. A pharmaceutical composition according to claim 33 in an injectable form. 35. The liposome composition according to claim 32 formed from a phospholipid and the phospholipid is phosphatidyl choline. 36. A method according to claim 1 wherein the cancer is melanoma. 37. A method according to claim 1 wherein the cancer is a carcinoma.

Details for Patent 6,290,929

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2039-02-26